ENTREPRENEURSHIP, INNOVATION, AND COMPETENCY-BASED EDUCATION - INTERVIEW WITH PROF. PAULO CÂMARA. ENGLISH VERSION
Background: The interview was conducted with Professor Paulo Wilton da Luz Câmara, who serves as an associate professor at the University of Vassouras, general coordinator of postgraduate lato sensu programs, and deputy coordinator of the Master's in Environmental Sciences. The Professor has extensive academic and corporate experience. Objectives: The main objectives were to understand the importance of corporate experience in the role of a professor and researcher, discuss the evolution of public entrepreneurship policies in Brazil, understand the role of incubators, explore research on renewable energies in the defense sector, and learn about planned innovations for postgraduate programs. Methods: The interview was conducted in a semi-structured format with open-ended questions. The audio was transcribed for subsequent analysis and content structuring. Results: Corporate experience significantly influences academic performance. There has been relative improvement in public entrepreneurship policies, but the involved bodies lack specific knowledge. Incubators are necessary tools to foster entrepreneurship and innovation. The main challenges in renewable energy research for defense are awareness and organizational policy. Planned innovations for postgraduate programs include connecting education levels, shared management, and an open committee. Discussion: The Professor highlights the importance of practical corporate experience in enriching academic performance, noting advances in entrepreneurship policies while emphasizing the need for more specific knowledge. Incubators are seen as essential to fostering entrepreneurship and innovation. In the field of renewable energy applied to defense, challenges are related to awareness and organizational policy. Conclusion: The interview underscores the relevance of practical corporate experience in enriching academic performance and the need to improve entrepreneurship policies. Incubators are fundamental to fostering entrepreneurship and innovation. Research on renewable energies in defense faces challenges of awareness and organizational policy. Planned innovations for postgraduate programs aim for greater integration and participation.
Read ArticleTREATMENTS FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A COMPARISON BETWEEN TISAGENLECLEUCEL AND CLOFARABINE
Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological malignancy predominantly affecting individuals under 20 years of age. Traditional chemotherapy, such as clofarabine, has shown efficacy; however, novel immunotherapeutic strategies like tisagenlecleucel (Kymriah®) have significantly altered the treatment paradigm. Aim: This study aimed to perform a comparative analysis of tisagenlecleucel, a CAR-T cell therapy, and clofarabine, a second-generation purine nucleoside analog, evaluating their mechanisms of action, therapeutic benefits, limitations, and clinical applicability across diverse patient populations. Methods: A systematic comparative evaluation was conducted, encompassing pharmacological characteristics, mechanisms of action, treatment protocols, efficacy, safety profiles, and clinical indications of both agents. The analysis considered pharmacokinetic and pharmacodynamic data and included patient demographic variables. Results: Tisagenlecleucel demonstrated high efficacy in refractory B-cell ALL, with durable responses and a blood half-life of 128 days, but with notable immune-related adverse effects such as cytokine release syndrome. Clofarabine, effective across a broader patient population, acts via multiple antitumor mechanisms but carries significant toxicity risks, including infection and sepsis. Discussion: The therapies present distinct clinical profiles: tisagenlecleucel offers targeted immunotherapy with high specificity but requires specialized infrastructure and management of immune toxicities. Clofarabine is more widely accessible and applicable, but is associated with conventional chemotherapy-related side effects. Treatment accessibility and cost differ markedly between the two. Conclusions: Therapy selection should be personalized based on patient-specific factors and institutional resources. Tisagenlecleucel is ideal for pediatric and young adult patients with relapsed/refractory B-cell ALL in CAR-T-capable centers, while clofarabine remains a viable option for broader ALL populations, particularly when genetic therapies are not feasible. Further research is needed to optimize therapeutic strategies and improve access to advanced treatments.
Read ArticleTHE ROLE OF EDUCATION IN FOSTERING ENTREPRENEURSHIP AND INNOVATION: INSIGHTS FROM DR. BHAVNA AMBUDKAR
Background: Dr. Bhavna, an experienced leader in education and innovation, has held various leadership positions, including head of department, dean of alumni relations, and president of the institutions innovation council. She has been instrumental in initiating the alumni cell at her previous organization and establishing world-class state-of-the-art laboratories in collaboration with the automotive sector. Aims: Dr. Bhavna's efforts aim to create an ecosystem for innovation and entrepreneurship within the institute and beyond, encouraging learners to consider entrepreneurship as a career option and fostering innovation in the electronics manufacturing domain. Methods: Dr. Bhavna's approach involves raising awareness about innovation and entrepreneurship among learners, fostering collaborations between academia and industry, and establishing world-class state-of-the-art laboratories to bridge the gap between academia and industry. Results: Dr. Bhavna's efforts have resulted in a strong alumni network, with graduates across the globe contributing to various domains and positions. She has also established world-class laboratories in collaboration with the automotive sector, fostering innovation and startups in the electronics manufacturing domain. Discussions: The Ministry of Electronics and Information Technology plays a significant role in initiating innovations and startups in the electronics manufacturing domain. They have generated a separate vertical for startups, which poses challenges to innovators. If a solution is validated, the ministry handholds the innovators, incubates their ideas, funds them, and helps them reach the market at the national and international levels. Conclusions: Dr. Bhavna's vision and efforts toward fostering an ecosystem for innovation and entrepreneurship within the institute and beyond are commendable. Her experience and achievements in various leadership roles, including as the head of the department and president of the institutions innovation council, have added significant value to her professional and personal life.
Read Article